食管原发性小细胞神经内分泌癌78例临床特点及预后分析

摘要

Objective To investigate the clinical features,treatment methods and prognosis in patients with esopha-geal primary small cell neuroendocrine carcinoma(ESCNC). Methods The clinical data and follow-up data of 78 pa-tients with ESCNC were collected and analyzed retrospectively from Oct. 2011 to Jun. 2017 in the First Affiliated Hospi-tal of Zhengzhou University. Results The 1-year, 3-year and 5-year survival rates were 55. 70%, 23. 87% and 13.82%, respectively. The median survivals of locally stage patients and advanced stage patients were 14 months and 7 months (P<0.05). The median survivals of locally stage patients with single treatment and with comprehensive treat-ment were 9 months and 17 months,respectively (P<0.05). Conclusion ESCNC is rare with high degree of malig-nancy. Diagnosis depends on histopathology and immunohistochemistry. At present,comprehensive treatment is the best choice for the patients in the locally stage.%目的 探讨食管原发性小细胞神经内分泌癌(esophageal primary small cell neuroendocrine carcinoma,ESCNC)的临床特征、治疗方法及预后情况.方法 回顾性分析2011年10月至2017年6月郑州大学第一附属医院经病理证实的ESCNC患者78例的临床及随访资料.结果 本组患者1、3、5年生存率分别为55.70%、23.87%和13.82%.局限期与广泛期患者的中位生存时间分别为14个月、7个月(P<0.05).局限期患者行单一治疗的中位生存时间为9个月,综合治疗为17个月(P<0.05).结论 ESC-NC是一种罕见且具高度侵袭性的恶性肿瘤,组织病理学及免疫组织化学检查是其确诊的主要手段.目前综合性治疗是局限期患者最好的选择.